Trials / Recruiting
RecruitingNCT06319872
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
Conditions
- Alcohol Use Disorder
- Retinal Dystrophies
- Age-Related Macular Degeneration
- Retinitis Pigmentosa
- Stargardt Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral disulfiram | 250 mg/day |
Timeline
- Start date
- 2025-05-19
- Primary completion
- 2029-05-19
- Completion
- 2029-05-19
- First posted
- 2024-03-20
- Last updated
- 2025-09-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06319872. Inclusion in this directory is not an endorsement.